Seaport Therapeutics presents additional Phase 1 PK data for GlyphAgo
PureTech says its Founded Entity, Seaport Therapeutics, presented additional pharmacokinetic data from a Phase 1 clinical trial of GlyphAgo™ at the ECNP congress.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
PureTech says its Founded Entity, Seaport Therapeutics, presented additional pharmacokinetic data from a Phase 1 clinical trial of GlyphAgo™ at the ECNP congress.